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Abstract
Background: This paper reports the duration of moderate and severe exacerbations in patients with house dust
mite induced allergic asthma and the impact on patients’ quality of life.
Methods: Post-hoc analyses were conducted using data collected during a phase III multi-national trial (MT-04) that
investigated time to moderate or severe asthma exacerbation among 485 patients during withdrawal from inhaled
corticosteroids. Patient diaries were analysed to ascertain duration of exacerbations. The impact on patients’ quality
of life was measured by calculating utilities for five health states using the EuroQol-5 Dimension (EQ-5D-3L) and
Asthma Quality of Life Questionnaire (AQL-5D). A regression analysis predicted the disutility of moving from ‘well
controlled asthma’ to the other four health states: ‘partially controlled asthma’, ‘uncontrolled asthma’, ‘moderate
exacerbation’ and ‘severe exacerbation’.
Results: Two hundred four patients experienced exacerbations. Moderate and severe exacerbations involved statistically
significant reductions in lung function compared to the constant peak expiratory flow observed for patients without
exacerbations. Lung function decline occurred for 28 days, decreasing approximately 14 days before an exacerbation
followed by a return to baseline over 14 days. Asthma symptoms, the use of short-acting β2-agonists, and frequency of
nocturnal awakening all increased, starting 10–14 days before an exacerbation, and returned to baseline within 10–28 days
following exacerbations. Compared to ‘well controlled asthma’, the disutility of having a ‘moderate exacerbation’ ranged
from − 0.0834 to − 0.0921 (EQ-5D-3L) and from − 0.114 to − 0.121 (AQL-5D); and of having a ‘severe exacerbation’ from −
0.115 to − 0.163 (EQ-5D-3L) and from − 0.153 to − 0.217 (AQL-5D), depending on the length of the observation period.
Conclusions: The impact of moderate and severe exacerbations in house dust mite induced allergic asthma extends 14
days before and 28 days after the peak exacerbation event. The impact of exacerbations on patients’ health-related quality of
life (HRQoL) continues long after their occurrence.
Keywords: Allergic asthma, Asthma, House dust mite allergic asthma, Asthma exacerbation, Exacerbation, Quality of life,
Utility
Background section
Allergic asthma (AA) is the most common type of
asthma [1]. It is a chronic global health problem ac-
counting for substantial morbidity and health-care ex-
penditures [2, 3]. The total annual cost of asthma in
Europe is estimated to be €19.3 billion [4]. Moderate
and severe exacerbations significantly increase asthma-
related and total health-care costs [5].
House dust mite (HDM) induced AA (HDM AA) is a
hypersensitivity reaction to inhaled airborne HDM aller-
gens. HDM is the most prevalent indoor allergen associ-
ated with asthma [6, 7], with 47.7% of European adults
with asthma sensitised to HDM allergens [8]. HDM AA
adversely impact patients’ health-related quality of life
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(HRQoL), both through asthma symptoms and exacer-
bations [9–12].
Exacerbations are serious complications of asthma,
characterised by episodes of acute deterioration of pro-
gressively worsening bronchial obstruction, which can
lead to shortness of breath, coughing, wheezing and/or
chest tightness [13]. Exacerbations may subside spontan-
eously or in response to treatment, but often require sys-
temic corticosteroids for 5 to 7 days [11]. Severe
exacerbations may require hospitalisation and can be
life-threatening [11, 14], and while they are more com-
mon with poorly controlled asthma [15], they can also
occur in mild [16, 17] or well-controlled asthma [18].
The Global Initiative for Asthma (GINA) outlines the
characteristics that determine whether patients are clas-
sified as having ‘well controlled’, ‘partly controlled’ or
‘uncontrolled’ asthma: daytime symptoms, limitations of
activities, nocturnal symptoms/awakening, need for re-
liever/rescue treatment, lung function and exacerbations
[19]. GINA recommends [19] that a patient’s level of
asthma control (their GINA “control status”) and
current treatment should determine what pharmacologic
treatment should be selected.
The only disease-modifying treatment for allergic dis-
ease including AA is allergy immunotherapy (AIT). AIT
has been shown to limit disease progression in children
with HDM allergy by preventing the development of
new allergic sensitisations [20]. HDM sublingual im-
munotherapy (SLIT) is recommended in the GINA
guidelines as a treatment for uncontrolled asthma with
exacerbations despite inhaled corticosteroids (ICS) pro-
vided the FEV1 is > 70% predicted [21].
The multinational European MT-04 trial was the
first trial to assess asthma exacerbations using AIT
[22]. Although exacerbations are a key outcome in
asthma research, trials often do not distinguish be-
tween moderate and severe exacerbations [23]. Lloyd
[12] investigated the impact of exacerbations on
HRQoL by different severity grades of exacerbations,
defined by what treatment was required to treat the
exacerbation. MT-04 was the first study to include an
assessment of both moderate and severe exacerbations
using the following definitions: the ATS/ERS defin-
ition of a moderate exacerbation translated into a
more measurable format suitable for a clinical trial
[24]; and the ATS/ERS description for severe exacer-
bations [13] (Table 1).
The current paper reports post-hoc analyses of the
MT-04 trial data that investigated the duration of both
moderate and severe exacerbations and their impact on
patients’ HRQoL, measured through utility. This is of
relevance as only limited data are available about exacer-
bation duration, with one patient survey suggesting that
this could be more than 21 days [23].
Methods
Study subjects
The MT-04 trial methods have been described in detail
elsewhere [22]. The relevant independent ethics commit-
tees and institutional review boards approved the trial
protocol and amendments in each of the 13 countries,
and the trial followed the principles of the Helsinki
Declaration.
Study design
This paper reports two post-hoc analyses of the Euro-
pean MT-04 phase III multi-national, randomised,
double-blind, placebo-controlled trial. The primary end-
point of MT-04 was time to first moderate or severe
asthma exacerbation during the period of ICS reduction
and withdrawal. The first post-hoc analysis investigated
the duration of exacerbations through an analysis of pa-
tients’ electronic diaries (e-diaries). The second analysis
derived utilities (patients’ preferences) for five mutually
exclusive asthma health states (well controlled, partially
controlled, uncontrolled, moderate and severe exacerba-
tion) derived from the trial data through a stepwise ap-
proach in order to measure the impact of asthma
control and exacerbations on patients’ HRQoL.
Methods
The MT-04 trial was divided into three periods (see
Fig. 1). In period 1 (5 to 7 weeks), patients were screened
and switched from their regular ICS asthma controller
to budesonide and SABA. Following randomisation to
either SQ® HDM SLIT-tablet (6 SQ-HDM or 12 SQ-
HDM) or placebo, patients continued with treatment
during period 2 (7–12months). In period 3, treatment
with SQ® HDM SLIT-tablet and placebo continued but
patients’ daily ICS was reduced by 50% for 3 months
(period 3A) and was then withdrawn for the next 3
months (period 3B).
The following data, relevant for the present post-hoc
analysis, were collected:
 E-diaries, capturing asthma symptoms (measured
using the Daily Symptom Score), SABA use (puffs
per day), nocturnal awakenings (times per night)
and lung function (PEF), were completed twice daily,
starting during the final 4 weeks of period 2 (defined
as period 2B) and continuing throughout period 3
(3A and 3B).
 Asthma Control Questionnaire (ACQ-7) data,
assessing patients’ asthma control on a 7-point scale
(0 = no impairment, 6 =maximum impairment) across
7 domains (the top scoring 5 symptoms, FEV1% pre-
dicted value and daily SABA use), were collected at 11
scheduled visits during periods 2 and 3.
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 The Asthma Quality of Life Questionnaire
(AQLQ) measuring the functional problems (in
physical, emotional, social and occupational
domains) that are most troublesome to adults
with AA was completed by patients once during
the middle of period 2 and five times throughout
period 3 (including at unscheduled visits due to
exacerbations) (Fig. 1). The AQLQ uses a 7-point
polytomous response scale ranging from 1 (se-
verely impaired) to 7 (not impaired at all) across
the four domains.
Analysis
The post-hoc analyses investigated the duration of mod-
erate and severe exacerbations through patient diary
data, and the impact of exacerbations on patients’
HRQoL by using AQLQ data to derive utilities.
Duration of exacerbations
E-diary data was used to visualise the duration of ex-
acerbations. Baseline-adjusted mean scores for e-diary
data for the 4 weeks before and after the patients’ first
exacerbation were compared to the final 8 weeks of
data for patients who did not experience exacerba-
tions. For subjects who did not exacerbate, the last 8
weeks of e-diary data were used as this period (3B,
ICS withdrawal) is when many exacerbations occur
and was expected to provide the most appropriate
control group.
Table 1 Definitions of moderate and severe exacerbations used in the MT-04 trial
Criteria defining moderate exacerbations [24] Criteria defining severe exacerbations [13]
1 or more of the following criteria and must also result in a temporary
change in treatment:
● Nocturnal awakening(s) due to asthma requiring SABA use for at least 2
consecutive nights or an increase of at least 0.75 points in daily symptom
score from baseline value on at least 2 consecutive days;
● An increase from baseline in SABA use on at least 2 consecutive days (a
minimum increase of 4 puffs per day);
● A 20% or more decrease in peak expiratory flow from baseline on at least
2 consecutive mornings or evenings or a 20% or more decrease in FEV1
from baseline;
● A visit to the emergency department or an unscheduled visit to the trial
site for asthma treatment not requiring systemic corticosteroids.
1 or more of the following criteria:
● A requirement for systemic corticosteroids for the treatment of
asthma symptoms for at least 3 days;
● An emergency department visit due to asthma requiring systemic
corticosteroids, or a hospitalization for more than 12 h due to asthma.
FEV1 Forced Expiratory Volume in 1 s, SABA Short-acting β2-agonists
Fig. 1 MT-04 trial design
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Deriving utilities
Utilities at each visit for 5 mutually exclusive asthma
health states were derived by mapping AQLQ data
(Fig. 2) using the definition of asthma exacerbations
used in the trial (Table 1) and GINA asthma control sta-
tus. AQLQ data for each patient was categorized into
the health states in a hierarchical approach at each
scheduled or unscheduled visit. If patients had an ex-
acerbation within a given number of days after a visit,
the AQLQ data was categorized as a moderate or severe
exacerbation at that visit. All remaining AQLQ data
points were grouped according to the GINA asthma
control status of the patient. Categorisation of control
status was done by mapping ACQ data to the GINA
asthma control status categories (Fig. 2) (well controlled,
partially controlled and uncontrolled) using a published
algorithm [25]. Observation periods of 7, 14, 21 and 28
days from an asthma exacerbation were used to include
AQLQ data, in order to explore how long the impact of
an asthma exacerbation on patients’ utility lasts.
Utility values were obtained in two ways: by mapping
to the Asthma Quality of Life Questionnaire (AQL-5D)
from AQLQ; and by mapping to the 3-level version of
the EuroQol-5 Dimension (EQ-5D-3L) from AQLQ. The
AQL-5D is derived from the AQLQ, a disease-specific
questionnaire, and can be used in economic evaluation.
It was decided to also map to EQ-5D-3L since data de-
rived using the EQ-5D-3L is generally preferred by
health technology assessment agencies when undertak-
ing economic evaluation. The two questionnaires use
different value sets to calculate the utility data, which re-
sults in similar, but not identical values.
The mapping from AQLQ to EQ-5D-3L and AQL-5D
was done using previously developed algorithms [26, 27].
The mapping produced utility values for each patient at
each scheduled and unscheduled visit in the trial. These
utilities were entered into a mixed effects ML regression
analysis, which estimated the predicted utility for well
controlled asthma, and the predicted disutility of moving
from well controlled asthma to the four health states of
Fig. 2 Overview of analysis conducted on the MT-04 trial data
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partially controlled asthma, uncontrolled asthma, mod-
erate exacerbation and severe exacerbation’ (Fig. 2). The
model of estimated EQ-5D-3L and AQL-5D can be seen
in Supplement 1.
Results
MT-04 patient details and asthma control
Seven hundred forty-two patients completed the trial
and were included in the full analysis set [22]. Four hun-
dred eighty-five patients received the active treatment
(237 6 SQ-HDM SLIT, 248 12 SQ-HDM SLIT) and 257
received a placebo. The patient baseline characteristics
and patient discontinuations are reported elsewhere [22].
At randomisation the percentage of patients reported to
have partly controlled asthma was similar in the two
groups (active treatment: 71%; placebo: 72%).
Duration of exacerbations
Two hundred four patients experienced a moderate or a
severe exacerbation during period 3 of the trial. E-diary
data demonstrated that moderate and severe exacerba-
tions involved statistically significant reductions in lung
function (morning and evening) compared to the aver-
age constant peak expiratory flow (PEF) observed for pa-
tients who did not experience exacerbations (Fig. 3). For
both moderate and severe exacerbations lung function
reduction occurred for about 28 days and started to de-
crease approximately 14 days before an exacerbation
followed by a gradual return to baseline over 14 days.
During both moderate and severe exacerbations,
asthma symptoms, SABA use, and the frequency of noc-
turnal awakening all increased, starting 10–14 days be-
fore an exacerbation and returned to baseline within
10–28 days following the exacerbation (Fig. 3).
There was a statistically significant difference in symp-
toms between those with moderate or severe exacerba-
tions compared to patients who did not experience
exacerbations (p < 0.05).
Utilities
Utility values were derived for five asthma health states:
well controlled, partially controlled, uncontrolled, mod-
erate and severe exacerbation (Table 2).
The utility values for the ‘well controlled asthma’ health
state were 0.923 (standard error (SE): 0.000716) for EQ-
5D-3L and 0.985 (SE: 0.000844) for AQL-5D. The disutil-
ity values of having ‘partially controlled asthma’ compared
to ‘well controlled asthma’, for each of the four cut-offs
for the number of days, ranged from − 0.0251 to − 0.0252
for EQ-5D-3L and − 0.0362 to − 0.0364 for AQL-5D; and
of having ‘uncontrolled asthma’ compared to ‘well con-
trolled asthma’, ranged from − 0.0632 to − 0.0634 for EQ-
5D-3L and − 0.0866 to − 0.0873 for AQL-5D.
Compared to ‘well controlled asthma’, the data for dis-
utility of having a ‘moderate exacerbation’ ranged from
− 0.0834 to − 0.0876 for EQ-5D-3L and − 0.114 to −
0.121 for AQL-5D; and of having a ‘severe exacerbation’
ranged from − 0.115 to − 0.163 for EQ-5D-3L and −
0.153 to − 0.217 for AQL-5D. Compared to ‘well con-
trolled asthma’, the disutility values of having exacerba-
tions were more than having partially controlled or
uncontrolled asthma.
Discussion
This post-hoc analysis demonstrates that the impact of
moderate and severe exacerbations in HDM AA extends
long before and after the peak exacerbation event. Symp-
toms and medication use increase up to 14 days prior to
the onset of an exacerbation. After the exacerbation, pa-
tients’ symptoms and medication use returns to baseline
more slowly than reported in the literature [28]. For ex-
ample, lung function took 14 days on average to return
to baseline and patients’ asthma symptoms, SABA use
and frequency of nocturnal awakening took between 10
and 28 days to return to baseline. This demonstrates that
PEF and symptomatic measures describe different as-
pects of asthma control and might not be useful as prox-
ies. Patients’ symptoms and medication use are also
affected for 14 days after an exacerbation.
Similarly, the impact of exacerbations on HRQoL (util-
ity) continues long after the occurrence of the exacerba-
tions. Not only do utility scores exhibit change over
several weeks around an exacerbation, but the size of the
change is also important. These analyses showed that AA
patients experience a reduction in HRQoL (disutility) that
is greater than 0.05 during moderate (range − 0.0834 to −
0.121) and severe (range − 0.115 to − 0.217) exacerbations,
as well as during times of uncontrolled asthma (range −
0.0632 to − 0.0873). The disutilities obtained by mapping
to AQL-5D were larger than those obtained by mapping
to EQ-5D. This may be due to the AQL-5D being a
disease-specific questionnaire and is therefore more sensi-
tive to the impact on subjects’ HRQoL.
MT-04 demonstrated that time to a first moderate or
severe exacerbation increases in patients who receive ac-
tive treatment [22]. Prolonging the time to exacerbation
means that patients experience a higher HRQoL for a
longer period of time and experience fewer symptoms
and require less reliever medication. The data for MT-
04 are consistent with data reported by Briggs [29] who
incorporated AQLQ data (from the Gaining Optimal
Asthma control (GOAL) study mapped to utility) to ana-
lyse the cost-effectiveness of asthma control treatment.
Briggs calculated a disutility of − 0.216 for exacerbations,
but did not distinguish between moderate and severe.
The definition of an exacerbation used in Briggs was
similar to that for ‘severe’ exacerbation used in MT-04.
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The largest disutility value calculated for MT-04 was −
0.217 for a severe exacerbation. Lloyd [12] reported that
EQ-5D was significantly worse for asthma patients ex-
periencing exacerbations. They reported the utility of pa-
tients not in exacerbation was 0.89, the utility of patients
in exacerbation without steroids was 0.57 and the utility
of patients in exacerbation and hospitalised was 0.33. Al-
though the patients in this trial had more severe asthma
than those in MT-04, the impact of exacerbations on
HRQoL in Lloyd et al. is similarly apparent.
The effect of asthma exacerbations on utilities is
greater in MT-04 than the disutilities for acute events in
other diseases. Harris [30] reported that non-severe
hypoglycaemia resulted in HRQoL decreases of between
− 0.0056 and − 0.0076 and decreases for severe
hypoglycaemia between − 0.0592 and − 0.0616. Davies
[31] reported disutilities for two acute events of − 0.06
for myocardial infarction and − 0.05 for unstable angina.
This analysis of MT-04 has shown that the effects of
asthma exacerbations can be experienced for weeks be-
fore and after the event, whereas events in other disease
areas can be much shorter. For example, prolonged
angina lasts more than 20min [32], typical chest pain in
acute myocardial infarction may last between 30 and 60
min [33] and the duration of a hypoglycaemic episode
may be minutes or hours [34].
A limitation of this study is that the definition of a
moderate asthma exacerbation was used for the first
time in the MT-04 trial and might have limited usability
in clinical practice. The number of exacerbations may be
considered small. This is a result of the trial design,
where patients were able to discontinue after the experi-
ence of the first asthma exacerbation or continue on an
increased ICS dose. This approach may be the reason
that few patients experienced more than one exacerba-
tion. For the current analysis, this means that the impact
of repeated exacerbations on HRQoL could not be mea-
sured. A further limitation was that the analyses did not
control for the timing between exacerbation occurrence
and AQLQ assessment. Finally, most of the trial analyses
described in this paper were post-hoc.
Future research in AIT should carefully consider the
method by which HRQoL is measured during exacerba-
tions so that the impact of exacerbations can be
Fig. 3 Duration of exacerbations
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captured accurately in terms of intensity as well as dur-
ation. Future modelling could analyse the relationship
between utility and duration of exacerbation. HRQoL
should also be measured in an AIT trial without ICS re-
duction and a primary endpoint which assesses the fre-
quency of exacerbations rather than time to
exacerbation. This would enable assessment of the im-
pact on HRQoL and the health economic impact of re-
peated exacerbations. Future asthma research should
seek to capture data on moderate exacerbations, to in-
crease our understanding of their effects compared to
severe exacerbations.
Conclusions
In conclusion, moderate and severe HDM AA exacerba-
tions lead to increases in symptoms and medication use
as well as reduction in lung function over a longer time
period than previously appreciated: up to 14 days prior
to an exacerbation and up to 28 days after [28]. Exacer-
bations, both moderate and severe, lead to a decrease in
HRQoL. Severe exacerbations lead to significantly more
variation in lung function, asthma symptoms, SABA use
and frequency of nocturnal awakening than moderate
exacerbations.
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